HL7 FHIR® Implementation Guide: Breast Cancer Data, Release 1 - US Realm (Draft for Comment)

This page is part of the Breast Cancer Data Logical Models and FHIR Profiles (v0.1.0: STU 1 Draft) based on FHIR R3. . For a full list of available versions, see the Directory of published versions

MammaprintRiskScoreInterpretationVS

{
  "resourceType" : "ValueSet",
  "id" : "oncology-MammaprintRiskScoreInterpretationVS",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns="http://www.w3.org/1999/xhtml">
<p><b>BC MammaprintRiskScoreInterpretationVS ValueSet</b></p>
<p>Intepretation of Mammaprint Recurrence Score</p>
</div>"
  },
  "url" : "http://hl7.org/fhir/us/breastcancer/ValueSet/oncology-MammaprintRiskScoreInterpretationVS",
  "identifier" : [
    {
      "system" : "http://hl7.org/fhir/us/breastcancer",
      "value" : "oncology.MammaprintRiskScoreInterpretationVS"
    }
  ],
  "version" : "0.1.0",
  "name" : "MammaprintRiskScoreInterpretationVS",
  "title" : "BC MammaprintRiskScoreInterpretationVS ValueSet",
  "status" : "draft",
  "date" : "2018-04-01T00:00:00+11:00",
  "publisher" : "The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC)",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "url",
          "value" : "http://standardhealthrecord.org"
        }
      ]
    }
  ],
  "description" : "Intepretation of Mammaprint Recurrence Score",
  "compose" : {
    "include" : [
      {
        "system" : "http://hl7.org/fhir/us/breastcancer/CodeSystem/oncology-MammaprintRiskScoreInterpretationCS",
        "concept" : [
          {
            "code" : "low_risk",
            "display" : "Score between 0.0 and +1.0, meaning a patient has on average a 10% chance that her cancer will recur within 10 years without any additional adjuvant treatment, either hormonal therapy or chemotherapy."
          },
          {
            "code" : "high_risk",
            "display" : "Score between -1.0 and 0.0, meaning a patient has a 29% chance that her cancer will recur within 10 years without any additional adjuvant treatment, either hormonal therapy or chemotherapy."
          }
        ]
      }
    ]
  }
}